drugset / Trial / NCT06333509
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
Timeline
- Start
- 2024-04-15
- Primary completion
- 2027-06-15
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT071 | Cell therapy | — | — |